BioCentury
ARTICLE | Translation in Brief

Tesla developing RNA therapeutic ‘microfactories’ for CureVac, plus CRISPR-directed RNA epigenetic modifications and Nucleix

BioCentury’s roundup of preclinical news

July 3, 2020 1:55 AM UTC

Tesla ‘microfactories’ for CureVac

Elon Musk tweeted on Wednesday that Tesla Grohmann Automation GmbH unit of Tesla Inc. (NASDAQ:TSLA) is building RNA “microfactories” for CureVac AG, which has an mRNA COVID-19 vaccine in the clinic. Prior to the emergence of SARS-CoV-2, the partners had filed a patent application covering a bioreactor -- including a portable apparatus that could deployed during pandemics -- capable of automated in vitro transcription under GMP-compliant conditions...